Design of ORCHESTRA Study: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease
Objective: To describe the practical management of foslevodopa/foscarbidopa (LDp/CDp) for treating advanced Parkinson’s disease (aPD) in routine clinical practice using data collected through a patient…Continuous Subcutaneous Dopaminergic Stimulation: Exploring the impact of Foslevodopa/Foscarbidopa on Gait in Parkinson’s disease.
Objective: The primary objective of this study is to investigate the effect of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (FL/FC) on gait in those with…The Impact of Statin Therapy on Motor and Non-Motor Symptoms in Parkinson’s Disease: A Meta-Analysis
Objective: To assess the effects of statin therapy on motor and non-motor symptoms in Parkinson’s disease (PD) through a meta-analysis of randomized controlled trials. Background:…Efficacy of LSVT-BIG Treatment Compared to Other Physiotherapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Objective: We aim is to assess the efficacy of Lee Silverman Voice Treatment-BIG therapy (LSVT-BIG) compared to other physiotherapy in patients with Parkinson's Disease (PwP).…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Relationship Between Improvement in “On” Time, Nonmotor Symptoms, and Quality of Life in Adults Treated With Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease
Objective: To determine if adults with advanced Parkinson’s disease (aPD) treated with a 24‑hour/day continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion who had ≥ 1‑hour improvement in…Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings.
Objective: To evaluate the impact of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa on bradykinesia, dyskinesia, and sleep quality using self-reported Hauser diaries and Parkinson’s KinetiGraph…Gastrointestinal Dysfunction and Levodopa Therapeutic Response in Parkinson’s Disease: A Brazilian Cross-sectional Study
Objective: To investigate the relation between constipation and the onset time of levodopa therapeutic effect in Parkinson's disease (PD). Background: Levodopa therapeutic response depends on…VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease
Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…
- « Previous Page
- 1
- …
- 349
- 350
- 351
- 352
- 353
- …
- 1942
- Next Page »